2019 Guest Speakers

 

 

 

 

 

Wednesday, November 6th:   8:00 a.m.  –  5:00 p.m.

Thursday, November 7th        8:00 a.m.  –  3:00 p.m.

 

Erik R. Dubberke, MD, MSPH  — Conference Chair
Dr. Dubberke, MD, MSPH is an Associate Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is an Associate Hospital Epidemiologist at Barnes-Jewish Hospital, Medical Director of Infection Control at Missouri Baptist Medical Center, and is the Director of the Section of Transplant Infectious Diseases at Washington University. He attended medical school at University of Illinois at Chicago, and did his medicine and infectious diseases training at Barnes-Jewish Hospital/Washington University.  He received a Master’s of Science in Public Health from St. Louis University.   His main research interests are in the epidemiology, diagnosis, treatment, and prevention of Clostridium difficile infection (CDI). Dr. Dubberke has over 115 publications, and made the Thomson Reuters list of Highly Cited Researchers in 2015 and 2016. He was the lead author for the CDI component of the Society for Healthcare Epidemiology of America (SHEA) Compendium to Prevent Healthcare Associated Infections, and is on the panel updating the SHEA/IDSA CDI clinical guidelines. He has also represented SHEA as a Key Informant for the AHRQ
Evidence-based Practice Center C. difficile review and at the Department of Health and Human Services Road Map to Eliminate HAI 2013 Action Plan Conference.
Presentation Topic:   “Community-Onset Clostridium difficile Infection.”

gerdingphotoDale Gerding, MD, FACP, FIDSA  — Conference Chair
Dr. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA) and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA.
Presentation Topic:   TBA

drpaulfeuerstadt Paul Feuerstadt, MD, FACG
Dr. Feuerstadt, MD, FACG,  is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training,
Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training.His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr.Feuerstadt is affiliated with St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT
Presentation Topic:   TBA

Nick VanHise, PharmD, BCPS
Dr. VanHise, PharmD, received a Bachelor of Science from Bradley University in Peoria, IL and his Doctorate of Pharmacy from Union University School of Pharmacy in Jackson, TN.Dr. Van Hise then went on to do an infectious disease residency and become board certified in pharmacoltherapy and infectious disease. Dr. Van Hise has been published in various scientific journals, including the New England Journal of Medicine, Clinical Infectious Diseases, and the Journal of Clinical Neuropharmacology.
Presentation Topic:  “The Preventative Approach to An Urgent
Threat; Clostridium difficile.

Glenn S. Tillotson, Ph.D., FRSM, FCCP
Dr. Tillotson, Ph.D., FRSM, FCCP has 30+ years pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. Dr Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin and other antibacterials. Glenn has held several key committee positions at the American College of Chest Physicians; he is on the Scientific Steering Committee for the GTCBio. Annual Summit on Anti-infective Partnering. Currently Dr. Tillotson has published >140 peer-reviewed manuscripts, presented >270 scientific posters and is on several journal Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine and F1000.
Presentation Topic:  TBA

Martha Cloakie, PhD, MSc, BSc
Dr. Martha Cloakie, PhD, MSc, BSc – Her research focuses on identifying, characterising and developing bacteriophages (viruses) that target and kill bacterial pathogens of medical relevance with the view to identifying novel antimicrobials.  Clearly this work has been impacted by our increasing concerns regarding antibiotic resistance because bacteriophages as natural enemies of bacteria can either be exploited as natural viruses, or they may encode novel products with antimicrobial properties. Her work is rooted in an ecological framework which I use both for virus discovery and the manipulation of microbiota associated with disease.  The major focus has been on Clostridium difficile where Dr. Cloakie has isolated and characterised a large bacteriophage collection, and where she has developed in vitro, ex situ and in vivo models to assess the mechanistic interactions of phages with their bacterial hosts and to assess their therapeutic potential.  Dr. Cloakie is now developing these phages as therapeutics.  Dr Cloakie obtained a BSc in Biology from Dundee University in 1996 an MSc in Biodiversity from Edinburgh University in 1997, and a PhD from Leicester in Molecular Ecology in 2001 and went on and did 6 years of Post-Doctoral research at the University of Warwick and in Scripps, La Jolla, San Diego.  In 2007 Dr Cloakie  was appointed as a lecturer at Leicester, in 2011 a Reader and in 2016 was promoted to Professor of Microbiology.
Presentation Topic:  TBA

Abhishek Deshpande, M.D., Ph.D
Dr. Abhishek Deshpande, M.D., Ph.D. is an Assistant Professor of Medicine at Cleveland Clinic Lerner College of Medicine and Associate Staff in the Department of Medicine and the Department of Infectious Diseases, at Cleveland Clinic. His research interests include evidence synthesis, comparative effectiveness, clinical practice guideline development and infectious diseases epidemiology. His research focuses on prevention of healthcare-associated infections with an emphasis on Clostridium difficile infection (CDI). His methods include large observational studies, evidence synthesis including meta-analyses, outcomes research and clinical trials. The overall goal of his research is to help reduce the burden and prevent hospital-acquired infections. Dr. Deshpande earned his medical degree from Manipal University, India and his PhD in biomedical sciences from the Kent State University/Cleveland Clinic Collaborative Program. He completed his postdoctoral fellowships from Cleveland Clinic and Case Western Reserve University.
Presentation Topic:  ” UV-C for C. difficile Disinfection – Implementation and Other Issues.”

Christopher Polage, MD, MAS
Dr. Polage, MD, MAS received a bachelor degree in Biology (1992) and Doctor of Medicine (2000) from the University of New Mexico where he was a post sophomore fellow in pathology and participated in infectious disease research involving Hantavirus. He completed a clinical internship in Internal Medicine at the University of Colorado and residency training in anatomic and clinical pathology at the University of Utah, receiving an award for research involving the identification of non-fermenting Gram negative bacteria via amplification and sequencing of 16s rDNA. He stayed in Utah to complete a two year fellowship in Medical Microbiology at ARUP Laboratories, serving as the Acting Assistant Medical Director of Mycobacteriology during his second year. Throughout his medical school, residency and fellowship training, Christopher Polage was actively involved in medical relief and research related work in the developing world including Peru and Africa and was partially supported as a Yale/Johnson & Johnson Physician Scholar in International Health in 2005. Dr. Polage is presently the Medical Director, DUHS Clinical Microbiology Laboratory, The Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University School of Medicine.
Presentation Topic: TBA

C. diff. Survivors
Mrs. Kathy Bischoff, and Mrs. Dayle Skelly and
Mrs. Tonya Harbour,  Mrs. Albah Muhfeld  –  C. diff. Survivors — join us to share their personal C. difficile infection journey; The signs, symptoms, treatments, with the physical, mental, and psycho-social changes endured from this life-threatening infection and how each recurrent
C. difficile infection (rCDI) impacted their lives.
Presentation Topic:   “A C. diff. Survivor’s Journey.”

Cliff-McDonaldClifford McDonald, MD
Dr. McDonald, MD graduated from Northwestern University Medical School. He completed a medical microbiology fellowship at Duke University and is a former member of CDC’s Epidemic Intelligence Service. Dr. McDonald is currently the Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC. He has first authored or co-authored over 100 peer reviewed publications on subjects related to healthcare and infectious disease epidemiology.
Presentation Topic:  “Clostridium difficile  2019 Updates From the Centers for Disease Control and Prevention (CDC) .”

Casey Theriot, PhD
Dr. Theriot, PhD, is an Assistant Professor in Infectious Disease at NC State University College of Veterinary Medicine in Raleigh, NC. She received a BES in Environmental Science from the University of Georgia, and her PhD in Microbiology from NC State University. She has also worked at the Centers for Disease Control and Prevention (CDC) as a Microbiologist. She completed a postdoctoral fellowship and independent research position with Dr. Vincent Young at the University of Michigan Medical School, where she focused on defining the gastrointestinal tract microbiome and metabolome during resistance and susceptibility to Clostridium difficile colonization and infection in a mouse model.
Presentation Topic: TBA

Mary Beth Dorr, PhD
Dr. Dorr, PhD is the product development lead for ZINPLAVA (bezlotoxumab), a monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Mary Beth has a pharmacy degree from the University of the Sciences’ Philadelphia College of Pharmacy and completed a clinical pharmacy residency at the Veteran’s Administration Hospital in Philadelphia. She received a PhD in pharmaceutics with an emphasis on pharmacokinetics and drug metabolism at the University of North Carolina Chapel Hill. Mary Beth joined the pharmaceutical industry in 1988, and has held a variety of positions related to the design and implementation of Phase 1 to 4 clinical trials, primarily for anti-infective products. Mary Beth has wide-ranging drug-development experience at several pharmaceutical companies, including Parke-Davis/Warner Lambert, Rhone-Poulenc Rorer/Aventis, Vicuron, and Wyeth/Pfizer, where she worked in pharmacokinetics/drug metabolism, clinical research, project and alliance management, and medical affairs. Mary Beth joined Merck in 2011 to direct the C. difficile monoclonal antibody clinical development program and led the clinical team through product registration and launch. In addition to her role as the product development team lead, she is responsible for the bezlotoxumab publication strategy and is the clinical director for the pediatric development program for bezlotoxumab.
Presentation Topic:    TBA

khanna_sahil_13ap-2

Sahil Khanna, MD, MBBS
Dr. Khanna, MD is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN.  His completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at University of California, San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty.  Dr. Khanna has completed Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations.  He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials at the May Clinic, Rochester, MN.
Presentation Topic:   “Fecal Transplant for C. difficile: Clinical Experience and Trials!”

Vince Wacher, PhD
Dr. Wacher, PhD is a biotechnology/pharmaceutical industry professional with over 22 years’ experience successfully leading corporate strategy, partnering, research, clinical, product development, and intellectual property programs for start-ups, small companies and new business units within large companies. He is currently engaged in product development, financing and partnering activities with Synthetic Biologics, Inc. Prior to his role with Synthetic Biologics, Vince was CEO of Verva Pharmaceuticals Ltd., where he advanced a repurposed medicine to successful phase 2 clinical proof-of-concept testing in type 2 diabetes and identified a new mitochondrial mode-of-action for the product with expansion applications in NAFLD/NASH, weight loss and mitochondrial diseases. Vince has designed, implemented, and/or analyzed discovery, preclinical and clinical programs in diverse therapeutic areas, including metabolic, cardiovascular, gastrointestinal, oncology, infection, immunosuppression, drug delivery and drug repurposing.
Presentation Topic:   TBA

Stuart B. Johnson, MD,FIDSA, DTM&H
Dr. Johnson, MD,FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus has involved the epidemiology pathogenesis, and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Presentation Topic:  TBA

Norman B. Javitt, MD, PhD
Dr. Javitt, MD is a research doctor in New York, New York. He received his medical degree from Duke University School of Medicine and has been in practice for more than 20 years. Education and Medical Training: Mount Sinai School of Medicine ,Residency , Internal Medicine,Mount Sinai School of Medicine Residency , Internal Medicine, Mount Sinai School of Medicine ,Internship , Transitional Year Duke University School of Medicine Medical School. Elected Member The American Society for
Clinical Investigation, 1969.
Presentation Topic:   TBA

simonheadshot-001

Simon M. Cutting, PhD
Professor Cutting of Molecular Microbiology at Royal Holloway, University of London is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus Clostridium difficile.. His other expertise is in the use of Bacillus spores as probiotics and has a number of contracts and consultancies with European and US companies in the food and feed sectors.
Presentation Topic:  TBA

Nicola Petrosillo, MD, FESCMID
Dr. Petrosillo, MD,FESCMID earned a degree of Doctor in Medicine and Surgery from the University “La Sapienza” in Rome, Italy in 1977; in the same University, he became specialist in Infectious Diseases (1981) and in Internal Medicine (1985). In 1981, he became hospital infectious diseases registrar and in 1999 Director of an Infectious Diseases Division at the National Institute for Infectious Diseases “Lazzaro Spallanzani” of Rome, Italy.He is fellow of the Pulmonary Vascular Research Institute and leader of the international task-force for pulmonary hypertension associated with HIV, since 2007. He is member of the Professional Affairs SubCommittee on Infectious Diseases and member of the Advisory Board of the Trainee Association of ESCMID. Additionally, he is Professor of Infectious Diseases at the Medical School of Specialization in Hygiene of the Tor Vergata University, Rome, and presently Director, Clinical & Research Department for Infectious Diseases National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS.
Presentation Topic:   TBA

A. Krishna Rao, MD, MS
Dr. Rao’s clinical, administrative, and research interests include the diagnosis and management of healthcare-associated infections, especially Clostridium difficile infection. His clinical work includes managing the University of Michigan Fecal Microbiota Transplantation (stool transplant) program for recurrent Clostridium difficile infection, a program that he co-founded. His primary research goal is to investigate how biochemical, microbiological, and clinical factors can help clinical decision-making in healthcare-associated infections, and he hopes to ultimately integrate these factors into robust risk-prediction algorithms for use by clinicians. He is currently funded by the NIH and/or CDC to study C. difficile infection, the effect of antibiotics on the gut microbiota, and infections from Gram-negative bacteria, including multi-drug resistant organisms, such as Klebsiella pneumoniae.
Presentation Topic:  TBA

Elaine Wang, MD, FIDSA
Dr. Wang, MD, FIDSA graduated from McGill University medical school and received a MSc in Clinical Epidemiology from McMaster University.  She was a practicing pediatric infectious disease specialist at The Hospital for Sick Children reaching a rank Associate Professor in Pediatrics at the University of Toronto, an appointment that she maintains.  She subsequently joined industry to pursue the development of a RSV vaccine. She has worked at Boehringer-Ingelheim, first in clinical development in Virology and Immunology, and then in medical affairs working on their treatment for an orphan disease, idiopathic pulmonary disease.  She has joined Seres Therapeutics to work on their proprietary microbiome-based interventions.
Presentation Topic:  “The Role of the Microbiome in a C. difficile Infection.

Mark Wilcox, MD, FRCPath
Dr. Wilcox, M.D., FRCPath, Conference Chair, serves as a Consultant Microbiologist, Head & Professor of Medical and Academic Lead of Pathology/Clinical Director of Pathology, at the Leeds Teaching Hospitals (LTHT). Dr. Wilcox is a Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences and is the lead on Clostridium difficile for Public Health England in the UK. Dr. Wilcox serves as the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents. He was the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at LTHT. He serves as Assistant Editor of the Journal of Antimicrobial Chemotherapy and Member of Council of the British Society of Antimicrobial Chemotherapy. Prof. Wilcox serves as a Member of the Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee and an Advisor to the UK Healthcare Commission, the Medicines and Healthcare products Regulatory Agency, the EPIC project on infection control issues, the Health Technology Assessment (HTA) program on Healthcare Associated Infection and the European Center for Disease Control. Dr. Wilcox serves as a Member of UK, European and US working groups on Clostridium difficile infection.
Presentation Topic:TBA

Dale Gerding, MD, FACP, FIDSA  and
Stuart B. Johnson, MD,FIDSA, DTM&H
Both Doctor Gerding, Conference Chair,  and
Doctor Johnson will present the latest data and discuss the topic of Antibiotics, the recommended treatments for a CDI and Recurrent – CDI’s with the medications available.

Arjun Srinivasan, MD
Dr. Srinivasan is the Associate Director for Healthcare Associated Infection Prevention Programs in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention. He is board certified in Infectious Diseases. Before coming to the CDC he was an Assistant Professor of Medicine in the Infectious Diseases Division at the Johns Hopkins School of Medicine where he was the Founding Director of the Johns Hopkins Antibiotic Management Program and the Associate Hospital Epidemiologist. His primary responsibilities include oversight and coordination of efforts to eliminate healthcare associated infections. A distinguished research scientist, his research and investigative areas of concentration include outbreak investigations, infection control, multi-drug resistant gram negative pathogens and antimicrobial use.
Presentation Topic:    TBA

 

 

 

 

# # # # # # # # # #

MEDIA IS WELCOME

Please contact the C Diff Foundation office:  info@cdifffoundation.org or (919)-201-1512

Qualifications and guidelines
Registration is complimentary for professional journalists attending the conference
to provide editorial coverage and who meet the eligibility criteria.

Conference Photography Provided by : Tony DelMonaco

AudioVisual:   PSAV St. Louis, MO

 

Follow us on Twitter

#Cdiff 2018

@cdiffFoundation